PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
Px Wire July-September 2022, Vol. 12, No. 2
Global Fund Investment Case: Seventh replenishment 2022 executive summary
The Global Fund’s analysis of the economic case for increased investment and commitment to its strategy pandemic preparedness and ending HIV, TB and malaria.
ViiV’s Community Stakeholder Engagement Strategy for Low- and Middle-Income Countries (2022-2024)
ViiV’s 2022-2024 strategy for community stakeholder engagement in low and middle income countries pledges a commitment to Good Participatory Practice Guidelines and more.
Px Wire April-June 2022, Vol. 12, No. 1
Newly relaunched, PxWire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research and development, implementation and advocacy. Download for a quick look at where we are in HIV prevention.
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (Summary)
AVAC published Translating Scientific Advance into Public Health Impact: A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP to provide a comprehensive view of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered in introducing injectable cabotegravir for PrEP. ViiV, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months, and this summary provides an overview of the plan.
MERL Handbook for Advocacy Champions
Everything you need to know about MERL for effective advocacy
This handbook has been put together from various training materials that have been utilized to build the MERL capacity of partners in the Coalition to build Momentum, Power, Activism, Strategy and Solidarity in Africa (COMPASS); between 2018 and 2021.
The overarching aim of this handbook is to enhance theimpact of campaigns; by empowering you with tools to monitor, evaluate and learn from your advocacy. This is a simple guide to understand advocacy MERL!
Translating Scientific Advance into Public Health Impact
A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP
AVAC’s Plan for Accelerating Access and Introduction of Injectable CAB for PrEP provides a comprehensive view of all the moving parts involved in delivering this new PrEP option and identifies priorities for ensuring time is not wasted and opportunity is not squandered. The plan focuses on learning the lessons from the first ten years of delivering oral PrEP and how to move faster, more strategically, and with greater coordination to maximize the impact of injectable CAB for PrEP.
Statement on the Dapivirine Ring for Women: Call for Accelerated Global Access
This statement, from a coalition of advocates, applauds the WHO for its ongoing support and its 2021 recommendation of the dapivirine vaginal ring as an additional prevention option for women. The advocates call on funders, country governments and community leaders to sustain their support for the ring’s introduction and rollout in African countries where it is needed and for prompt regulatory reviews. And they call on HIV programs to integrate the ring, and collaborate with communities on the design of those programs.
Consultation avec les parties prenantes de la PF/SSR sur la pilule de double protection
Ce rapport résume et rapporte les prochaines étapes d’une consultation organisée par AVAC et FP2030 avec les parties prenantes de la planification familiale (PF) et de la santé sexuelle et reproductive (SSR). L’objectif de la consultation était de comprendre les points de vue uniques des parties prenantes sur la pilule de double prévention (DPP), une pilule orale quotidienne qui prévient le VIH et la grossesse.
Click here for the English version.
Consultation with FP/SRH Stakeholders on the Dual Prevention Pill
This report summarizes and reports next steps from an AVAC and FP2030 convened consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders. The aim of the consultation was to understand stakeholders’ unique perspectives on the Dual Prevention Pill (DPP), a daily oral pill that prevents HIV and pregnancy. The consultation helped to elevate questions and issues to consider as DPP introduction plans are refined and that can also inform the development and delivery of future multi-purpose prevention technologies (MPTs).